
Outset Medical OM
$ 4.19
0.24%
Annual report 2025
added 02-13-2026
Outset Medical Book Value 2011-2026 | OM
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Outset Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 M | 26.8 M | 123 M | 246 M | 374 M | 329 M | -372 M | -288 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 374 M | -372 M | 70.6 M |
Quarterly Book Value Outset Medical
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 M | 26.8 M | - | - | - | - | 345 M | 374 M | 410 M | 431 M | 307 M | 329 M | 329 M | 329 M | 329 M | 37.3 M | 37.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 431 M | 26.8 M | 263 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.86 | -1.72 % | $ 1.74 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Electromed
ELMD
|
43.2 M | $ 25.1 | -0.59 % | $ 212 M | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
EDAP TMS S.A.
EDAP
|
50.1 M | $ 3.36 | 1.46 % | $ 126 M | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 10.57 | 2.2 % | $ 299 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.63 | -1.29 % | $ 39.2 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 2.0 | 1.01 % | $ 1.22 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.09 | 5.9 % | $ 18.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 14.76 | 0.82 % | $ 346 M | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.28 | -13.01 % | $ 906 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 58.53 | -0.66 % | $ 3.19 B | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 88.23 | 0.49 % | $ 11.9 B | ||
|
Delcath Systems
DCTH
|
111 M | $ 10.25 | 0.39 % | $ 367 M | ||
|
Insulet Corporation
PODD
|
1.52 B | $ 169.75 | 6.08 % | $ 11.9 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 38.59 | 7.31 % | $ 1.2 B | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 53.41 | - | $ 1.57 B | ||
|
Sintx Technologies
SINT
|
2.93 M | $ 2.0 | 0.5 % | $ 5.55 M | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 83.01 | -0.79 % | $ 2.88 B | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 80.96 | -0.32 % | $ 47.3 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Stryker Corporation
SYK
|
22.4 B | $ 314.5 | -0.2 % | $ 120 B | ||
|
Tactile Systems Technology
TCMD
|
219 M | $ 22.53 | 0.13 % | $ 515 M | ||
|
TELA Bio
TELA
|
6.31 M | $ 0.84 | -1.79 % | $ 39.4 M | ||
|
TransMedics Group
TMDX
|
473 M | $ 98.83 | 0.26 % | $ 3.36 B | ||
|
Tandem Diabetes Care
TNDM
|
155 M | $ 18.77 | 3.33 % | $ 1.28 B | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.38 | -0.19 % | $ 64.3 M | ||
|
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.25 | 4.17 % | $ 50.9 M |